Global Peramivir Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Peramivir Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Paramivir is a synthetic cyclopentane derivative. Functional groups which get connected to the loop include hydrophilic carboxyl and guanidine groups, as well as hydrophobic isopentyl and acetamido groups. The four functional groups with different polarities act on different active site regions in the NA structure of influenza viruses. This medicine is suitable for the treatment of influenza A. It is mainly administered intravenously in the form of sodium chloride solution.
Peramivir report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Peramivir market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Demand from Influenza A Treatment and Influenza B Treatment are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Peramivir industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034.
Globally, Peramivir key manufacturers include BioCryst Pharmaceuticals, Green Cross Pharma, Shionogi Co., NeoPharm, Moksha8 Pharma, NT Pharma, Merck, Hikma Pharmaceuticals and Hunan Nucien Pharmaceutical Co., Ltd., etc. BioCryst Pharmaceuticals, Green Cross Pharma, Shionogi Co. are top 3 players and held % sales share in total in 2022.
Peramivir can be divided into Solution and Solid, etc. Solution is the mainstream product in the market, accounting for % sales share globally in 2022.
Peramivir is widely used in various fields, such as Influenza A Treatment and Influenza B Treatment, etc. Influenza A Treatment provides greatest supports to the Peramivir industry development. In 2022, global % sales of Peramivir went into Influenza A Treatment filed.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Peramivir market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
BioCryst Pharmaceuticals
Green Cross Pharma
Shionogi Co.
NeoPharm
Moksha8 Pharma
NT Pharma
Merck
Hikma Pharmaceuticals
Hunan Nucien Pharmaceutical Co., Ltd.
SCOLR Pharma
Segment by Type
Solution
Solid
Influenza A Treatment
Influenza B Treatment
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Peramivir market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Peramivir, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Peramivir industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Peramivir in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Peramivir introduction, etc. Peramivir Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13QYResearch’s Conclusions of Peramivir market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by QYResearch.
Peramivir report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Peramivir market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Demand from Influenza A Treatment and Influenza B Treatment are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Peramivir industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034.
Globally, Peramivir key manufacturers include BioCryst Pharmaceuticals, Green Cross Pharma, Shionogi Co., NeoPharm, Moksha8 Pharma, NT Pharma, Merck, Hikma Pharmaceuticals and Hunan Nucien Pharmaceutical Co., Ltd., etc. BioCryst Pharmaceuticals, Green Cross Pharma, Shionogi Co. are top 3 players and held % sales share in total in 2022.
Peramivir can be divided into Solution and Solid, etc. Solution is the mainstream product in the market, accounting for % sales share globally in 2022.
Peramivir is widely used in various fields, such as Influenza A Treatment and Influenza B Treatment, etc. Influenza A Treatment provides greatest supports to the Peramivir industry development. In 2022, global % sales of Peramivir went into Influenza A Treatment filed.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Peramivir market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
By Company
BioCryst Pharmaceuticals
Green Cross Pharma
Shionogi Co.
NeoPharm
Moksha8 Pharma
NT Pharma
Merck
Hikma Pharmaceuticals
Hunan Nucien Pharmaceutical Co., Ltd.
SCOLR Pharma
Segment by Type
Solution
Solid
Segment by Application
Influenza A Treatment
Influenza B Treatment
Segment by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Peramivir market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Peramivir, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Peramivir industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Peramivir in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Peramivir introduction, etc. Peramivir Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13QYResearch’s Conclusions of Peramivir market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by QYResearch.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices